Next Article in Journal
Molecular Effect of Variants in Toll-like Receptor 4 Gene in Saudi Patients with Type 2 Diabetes Mellitus
Previous Article in Journal
The Cell-Autonomous Pro-Metastatic Activities of PD-L1 in Breast Cancer Are Regulated by N-Linked Glycosylation-Dependent Activation of STAT3 and STAT1
Previous Article in Special Issue
From Molecules to Imaging: Assessment of Placental Hypoxia Biomarkers in Placental Insufficiency Syndromes
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Cells
Volume 12
Issue 19
10.3390/cells12192339
cells-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins

by
Lauren Sayres
1,
Amanda R. Flockton
2,
Shuhan Ji
2,
Carla Rey Diaz
2,†,
Diane L. Gumina
2 and
Emily J. Su
1,2,*
1
Division of Maternal Fetal Medicine, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado, CO 80045, USA
2
Division of Reproductive Sciences, Department of Obstetrics and Gynecology, University of Colorado School of Medicine, Aurora, Colorado, CO 80045, USA
*
Author to whom correspondence should be addressed.
†
In memoriam.
Cells 2023, 12(19), 2339; https://doi.org/10.3390/cells12192339
Submission received: 21 July 2023 / Revised: 19 September 2023 / Accepted: 21 September 2023 / Published: 23 September 2023
(This article belongs to the Special Issue Etiopathogenesis and Sequelae of Intrauterine Growth Restriction: Cellular and Molecular Mechanisms)
Browse Figures
Review Reports Versions Notes

Abstract

:
Severe fetal growth restriction (FGR) is characterized by increased placental vascular resistance resulting from aberrant angiogenesis. Interactions between endothelial cells (ECs) and the extracellular matrix (ECM) are critical to the complex process of angiogenesis. We have previously found that placental stromal abnormalities contribute to impaired angiogenesis in severe FGR. The objective of this research is to better characterize the effect of individual ECM proteins on placental angiogenic properties in the setting of severe FGR. ECs were isolated from human placentae, either control or affected by severe FGR, and subjected to a series of experiments to interrogate the role of ECM proteins on adhesion, proliferation, migration, and apoptosis. We found impaired proliferation and migration of growth-restricted ECs. Although individual substrates did not substantially impact migratory capacity, collagens I, III, and IV partially mitigated proliferative defects seen in FGR ECs. Differences in adhesion and apoptosis between control and FGR ECs were not evident. Our findings demonstrate that placental angiogenic defects that characterize severe FGR cannot be explained by a singular ECM protein, but rather, the placental stroma as a whole. Further investigation of the effects of stromal composition, architecture, stiffness, growth factor sequestration, and capacity for remodeling is essential to better understand the role of ECM in impaired angiogenesis in severe FGR.

1. Introduction

Fetal growth restriction (FGR) is a pathologic condition whereby a fetus does not meet its growth potential [1]. FGR is a leading cause of perinatal morbidity and mortality and confers risk for lifelong adverse health outcomes [2,3,4]. Outcomes are substantially worse in the severe, early-onset phenotype of FGR, defined by an estimated fetal weight or abdominal circumference less than the third percentile or abnormal umbilical artery Doppler velocities diagnosed before 32 weeks [5,6,7]. When Doppler abnormalities have progressed to absent or reversed umbilical artery velocities, there is high risk for perinatal death [8,9,10,11]. Among survivors, there remains substantial risk for adverse early and long-term outcomes [12,13]. To date, there are no effective prophylactic or therapeutic measures for FGR [1]. Thus, following a diagnosis of severe FGR, clinicians are resigned to increased antenatal surveillance and early delivery in order to minimize exposure to the abnormal intrauterine environment and attendant risk of fetal demise [1]. Advancing our understanding of the pathophysiology of FGR is critical to improving outcomes for pregnant women and their offspring.
Abnormal umbilical artery Doppler velocimetry, an indicator of placental insufficiency, is a key finding in severe FGR [14]. Placentae complicated by FGR specifically with absent or reversed umbilical artery Dopplers demonstrate sparse villous vasculature [15,16,17,18,19,20]. This leads to deficient oxygen and nutrient delivery to the fetus and increased fetal cardiac and metabolic strain, key pathophysiologic causes underlying the risk for adverse outcome [15,17]. This aberrant vasculature results from a number of mechanistic pathways that remain poorly understood [21,22]. In particular, to maintain a healthy vascular bed and function, fetoplacental angiogenesis must increase exponentially in the second half of gestation; in severe FGR, this process has been found to be significantly impaired [16].
Angiogenesis entails the complex process of sprouting a new blood vessel from an existing vessel [23]. Endothelial cells (ECs) that line the original vessel must appropriately interact with the surrounding extracellular matrix (ECM), resulting in proliferation, outward migration, and luminal formation. The role of the ECM as a critical source of angiogenic regulatory factors and as a mediator of EC function in other human tissues has been established [24,25]. Ongoing research has suggested that specific characteristics of the ECM, such as protein composition and stiffness, may similarly impact placental angiogenic function [26,27,28,29].
Our laboratory previously demonstrated that human ECs primarily isolated from placentae affected by severe FGR exhibited impaired angiogenesis relative to ECs derived from control placentae [30]. Ongoing efforts have focused on the interaction between ECs and their microenvironment [29]. This work reveals that when ECs obtained from control placentae are plated on cell-derived matrix (CDM) generated from fibroblasts of growth-restricted placentae, these control ECs exhibit impaired angiogenic properties. In contrast, the inherent angiogenic defects of FGR ECs can be partially rescued when plated on control CDM. Together, these underscore the importance of matrix composition on regulation of EC function. Further interrogation of FGR CDM has also suggested a deficiency in expression and deposition of certain stromal proteins, including fibronectin and collagen I.
The objective of this study is to characterize the effects of individual ECM proteins on the angiogenic properties of human placental ECs in severe FGR with abnormal Doppler velocimetry. Specifically, we have evaluated adhesion, proliferation, migration, and apoptosis of ECs derived from FGR and control placentae in the presence of several ECM proteins [29,31]. The individual proteins—fibronectin; collagens I, III, and IV; laminin; thrombospondin; and fibrinogen—were chosen as prior efforts have revealed these to be abundant in the placental stromal matrix and because they are plausible mediators of fetoplacental angiogenic function [29,31,32]. Our central hypothesis is that the impaired angiogenesis characteristic of severe FGR will be partially rescued in the presence of certain ECM proteins including collagen I.

2. Materials and Methods

2.1. Subject Selection

This study was approved by the Colorado Multiple Institutional Review Board (COMIRB study IDs 14-1073 and 15-0365). Eligible subjects were identified and approached by our institution’s Perinatal Research Core. All subjects provided informed consent to participate.
All subjects were patients of the obstetric service at a tertiary academic hospital. Subjects affected by FGR had an estimated fetal weight or abdominal circumference below the 10th percentile with absence or reversal of umbilical artery diastolic flow diagnosed before 32 weeks. Fetal growth was estimated using the Hadlock algorithm. Fenton birthweight percentiles were used to confirm normal or restricted growth. Control subjects delivered a normally grown neonate at term. All deliveries occurred via unlabored cesarean section. Exclusion criteria included use of in vitro fertilization for conception, multiple gestation, fetal anomaly or aneuploidy, maternal infection, or maternal condition that could result in uteroplacental insufficiency, such as diabetes, antiphospholipid antibody syndrome, or substance use. Of note, any form of hypertension, including preeclampsia, was not considered an exclusion criterion for the FGR cohort, as the vast majority of subjects with severe FGR at our institution exhibited a concomitant diagnosis.

2.2. EC Isolation and Culture

Placentae were obtained immediately following delivery. Primary fetoplacental villous macrovascular ECs were isolated using previously described methods [29]. ECs were cultured in microvascular endothelial cell growth medium containing 5% fetal bovine serum, bovine brain extract, human epidermal growth factor, hydrocortisone, gentamicin, and amphotericin B (Lonza Bioscience; Walkersville, MD, USA), except where noted. ECs were cultured in a humidified incubator at 37 °C with 5% CO2. ECs between the third and fifth passages were used in all experiments, and passages were matched as best as possible within each experiment in order to mitigate potential effects of passage on phenotype. Technical triplicates were performed except where noted. Figure 1 depicts the experimental design.

2.3. EC Adhesion

CytoSelect Cell Adhesion Assay Kit (Cell Biolabs; San Diego, CA, USA) was used in accordance with the manufacturer’s instructions to evaluate EC adhesion to various ECM substrates, including fibronectin, collagens I and IV, laminin, and fibrinogen. ECs from control and severe FGR placentae were suspended at a concentration of 5 × 105 cells/mL in serum-free endothelial cell growth medium (Lonza Bioscience). The cell suspension was applied to each substrate-coated well and incubated at 37 °C for 60 min. Each well was serially washed, and cell stain and extraction solutions were sequentially applied. Samples were transferred to a microtiter plate, and optical density at 560 nm was determined using a plate reader. Colorimetric measurements were standardized to those of both negative experimental controls (wells coated with bovine serum albumin) and negative technical controls (no cells added to the wells).

2.4. EC Proliferation

Live cell microscopy was used to determine EC proliferation on various ECM substrates. Fibronectin; collagens I, III, and IV; laminin; and thrombospondin were diluted in phosphate-buffered solution (PBS) to a concentration of 10 μg/mL. Equal volumes of 30 μL of each substrate were applied to individual wells of a microtiter plate and allowed to coat the wells over two hours on an orbital shaker. The wells were then washed, and ECs were plated at a density of 2.5 × 103 cells/mL into each well. The plates were incubated at 37 °C for 5 d, with live cell microscopy performed every 24 h, including at time of initial plating. ECs were counted using calibrated software, Incucyte Live Cell Analysis (Sartorius, Öttinger, Germany). A total of four technical replicates were performed per subject for each ECM substrate. This particular experiment was performed on cells from 14 subjects, 7 controls and 7 with severe FGR.

2.5. EC Migration

Migration of ECs in the presence of various ECM substrates was determined via wound scratch assay. Similar to the proliferation experiment, equal volumes and concentrations of fibronectin; collagens I, III, and IV; laminin; and thrombospondin were individually coated on a microtiter plate. After a two-hour incubation, the wells were washed, and ECs were plated at a density of 5.5 × 104 cells/mL into each well. The ECs were incubated at 37 °C for 18 h, ensuring 100% confluence was achieved. A wound scratch was then performed with the Incucyte WoundMaker (Sartorius), and the wells were washed with culture medium to remove debris. Live cell microscopy was performed at baseline, confirming initial confluence of the cells and quality of the wound scratch, and every three hours for a total 24 h period. Following iterative calibration, Incucyte Live Cell Analysis was performed to determine the relative wound density. Relative wound density is defined as the proportion of the initial wound scratch occupied by cells at a given time point and accounts for temporal changes in the background, non-wound, and wound density. A total of at least three technical replicates were performed per subject for each ECM substrate.

2.6. EC Apoptosis

Apoptosis of ECs in the presence of each ECM substrate was determined by performing automated capillary immunoblotting for cleaved caspase-3, a protein in the apoptosis pathway, and total caspase-3 as a positive control. Individual plates were coated with 1 mL of 10 μg/mL fibronectin; collagens I, III, and IV; laminin; and thrombospondin and allowed to incubate for two hours. Plates were washed, and 5 × 104 cells/mL were applied to each plate. After a 5 d incubation at 37 °C, the ECs were washed with PBS and detached from the plates using trypsin. The ECs were serially centrifuged with culture medium then PBS followed by aspiration of the supernatant after each step. Next, 70 μL of Mammalian Protein Extraction Reagent (M-PER™) containing protease and phosphatase inhibitors (Thermo Fisher Scientific; Waltham, MA, USA) was applied to each tube of ECs. Protein extraction was allowed to occur over a 20 min period by maintaining the cell solution on ice with frequent vortexing. The extracted proteins were then centrifuged and stored at −80 °C for later use. As a positive apoptotic control, ECs that had been treated with 5% ethanol for 30 min underwent the same protein extraction process.
Protein concentration was calculated using a standard bicinchoninic acid protein assay kit (Thermo Fisher Scientific). Automated Jess capillary-based immunoblotting (Bio-Techne; Minneapolis, MN, USA) was performed to detect cleaved and total caspase-3 in accordance with the manufacturer’s instructions. Protein samples were loaded into the microplate at a concentration of 0.3 μg/μL. Primary rabbit antibodies to cleaved caspase-3 at a dilution of 1:10 (Cell Signaling Technologies; Danvers, MA, USA, 9661s) and total caspase at a dilution of 1:500 (Cell Signaling Technologies; 9662s) were selected based on our prior optimization efforts [29]. Expected molecular weights are approximately 17 and 19 kDa for cleavage products of caspase-3 and 36 kDa for total caspase-3 [33]. A total protein normalization package (Bio-Techne) was employed to ensure consistent protein loading across samples. Single replicates were run for each EC phenotype in the presence or absence of each ECM substrate given consistent findings across all samples and subjects. Both negative and positive apoptosis controls were included in each Western blot run to ensure accurate interpretation.

2.7. Statistical Analysis

An a priori power calculation was performed, demonstrating that eight subjects per group were required for 90% power (α = 0.05) to detect a biologically significant 10% difference in average migratory capacity. Shapiro–Wilk testing did not suggest non-Gaussian distributions for outcomes with continuous variables for either control or FGR ECs. Clinical characteristics between control and FGR subjects were compared using Fisher’s exact test, student’s t test, or Welch’s t test, as applicable. EC adhesion, proliferation, and migration were compared using two-way analysis of variance (ANOVAs) followed by Šidák’s tests when applicable. EC adhesion based on substrates was also compared using a two-way ANOVA followed by Tukey’s multiple comparisons tests when applicable. EC apoptosis was assessed by evaluating the area under the curve at the expected molecular weights for cleaved and total caspase-3 on Western blot images. Alpha significance level was set to a p value of less than 0.05. Error bars in all figures represent the standard error of the mean. Commercially available statistical software (GraphPad Prism 9; GraphPad Software; Boston, MA, USA) was used.

3. Results

3.1. Subject Characteristics

Demographic and clinical characteristics of all subjects are presented in Table 1. Included are a total of 16 subjects, of whom 8 were diagnosed with severe FGR and 8 represented term controls. As expected, there were significant differences between control and severe FGR subjects with regard to gestational age at delivery (39 v. 28 weeks, p < 0.0001), neonatal birth weight (3220 v. 647 grams, p < 0.0001), and Fenton percentile (43 v. 3, p = 0.002). Nulliparity was less common among control subjects relative to those diagnosed with FGR (0% v. 38%, p = 0.03). While there was no significant difference in proportion of fetal sex between the two cohorts, there was a slight skew toward more male fetuses with FGR (five male, three female) as compared to control subjects, which were evenly distributed (four male, four female). All subjects with FGR displayed absent or reversed umbilical artery Doppler flow; no control subjects had this finding.

3.2. EC Adhesion

First, we sought to determine whether adhesion of ECs varies in the setting of different ECM substrates. We evaluated adhesion of control and severe FGR ECs to five ECM proteins: fibronectin, collagen I, collagen IV, laminin, and fibrinogen. We found no difference in the adhesion of control relative to FGR ECs on each individual substrate (Figure 2). There were also no sex-specific differences in adhesive capacity (Figure S1). However, when comparing adhesion of all ECs by ECM protein (Figure 2), significant differences were found. Relative to laminin, adhesion of all ECs to fibronectin (p = 0.001), collagen I (p = 0.0002), and collagen IV (p < 0.0001) was significantly increased. Similarly, as compared to fibrinogen, ECs from both cohorts also displayed enhanced adhesion to collagen I (p = 0.02) and collagen IV (p = 0.009) (Figure 2). Together, these data suggest that although there is no difference in adhesion between control and FGR ECs, ECs still exhibit preferential binding to certain stromal ECM proteins.

3.3. EC Proliferation

Next, we compared the growth of control and FGR ECs when plated on each of six ECM substrates—fibronectin, collagens I, III, and IV, laminin, and thrombospondin—and on uncoated plates. Overall, when combining all substrate and uncoated conditions, there was significantly less proliferation in FGR ECs as compared to control ECs (p = 0.002), with post hoc comparisons demonstrating significant differences at days 3 (p = 0.003), 4 (p = 0.0007), and 5 (p = 0.01) (Figure 3A). However, there were no significant differences between control and severe FGR EC proliferation once they were stratified by substrate (Figure 3B). Further analysis demonstrated that as compared to lack of ECM substrate, collagen I, collagen III, and collagen IV promoted FGR EC proliferation (Figure 3C). In contrast, there was no statistical improvement in control EC proliferative capacity in the setting of any ECM protein (Figure 3C). This suggests the possibility of a differential response of control and FGR ECs to certain ECM proteins, such that these proteins may partially rescue proliferative capacity in severe FGR. When analyzed by fetal sex, proliferation curves were not significantly different between male and female subjects (Figure S2).

3.4. EC Migration

Our next step was to evaluate the migration of third or fourth passage ECs across a wound scratch over a 24 h period in the presence or absence of ECM proteins. With all substrates combined, FGR ECs exhibited decreased migration as compared to control ECs (p < 0.0001) (Figure 4A; representative images of substrates with statistically significant differences shown in Figure S3). Post hoc comparisons demonstrate significant differences at 3, 6, 9, 12, 15, and 18 h (p < 0.0001 for all timepoints) and 21 h (p = 0.01). FGR ECs continued to demonstrate significantly decreased migratory capacity in the absence of ECM substrate (p = 0.04) or in the presence of fibronectin (p = 0.04), collagen I (p = 0.048), or laminin (p = 0.03) (Figure 4B), suggesting that these substrates do not substantially alter control or FGR EC motility. Furthermore, there were no significant differences at each individual timepoint for any of these substrates with post hoc testing. With regard to collagen III, collagen IV, and thrombospondin, there were no significant differences between control and FGR EC migratory capacity. However, further comparison of either control or severe FGR ECs in the presence of each substrate relative to migration on uncoated plates did not demonstrate any significant differences in either cohort (Figure 4C). Together, our data indicate that no specific ECM protein rescues FGR EC migration. Notably, both control and severe FGR ECs isolated from placentae of female fetuses exhibited significantly improved migration relative to males (Figure S4). In fifth passage ECs, control and FGR ECs on uncoated plates displayed similar rates of migration (p = 0.37, Figure S5A). This finding persisted in the presence of all individual substrates (Figure S5B), suggesting that passage number may impact specific angiogenic properties.

3.5. EC Apoptosis

Finally, we sought to assess whether apoptosis of ECs differed in the presence of individual ECM substrates. We performed automated capillary immunoblotting on proteins extracted from control and severe FGR ECs cultured for five days on substrate-coated or uncoated plates. We detected the expression of total caspase-3, an expected protein in live cells, across all control and FGR ECs cultured in the presence or absence of any ECM substrates. However, cleaved caspase-3, a marker of apoptosis, was not detected in either control or FGR ECs when cultured with or without individual ECM substrates as compared to a positive apoptotic control of fetoplacental ECs treated with 5% ethanol for 30 min (Figure 5). All Western blots produced identical results with complete absence of cleaved caspase-3 in all control or FGR EC subjects regardless of substrate, with the exception of the positive control. Summarily, these results demonstrate that apoptosis was not induced in either cohort regardless of ECM substrate and, thus, cannot explain our other findings of differential adhesion, proliferation, or migration.

4. Discussion

Placental vascular development is critical to its function in delivery of oxygen and nutrients to the fetus and fetal cardiac dynamics. In particular, inappropriately sparse vasculature is evident in severe FGR and associated with morbidity and mortality. Placental ECs do not operate in vacuo but rather are surrounded by a complex extracellular environment that affects their angiogenic potential [29,34]. We previously demonstrated the existence of a unique ECM signature among FGR placentae, with decreased, disordered deposition of certain stromal proteins, including fibronectin and collagen I, but no difference in thrombospondin-1, in FGR CDM [29]. However, subsequent work suggested no significant improvement in severe FGR EC migratory capacity in the presence of fibronectin [35]. Thus, we hypothesized that exposure of severe FGR ECs to other ECM proteins, specifically collagen I, would partially rescue the impaired angiogenic properties seen at baseline.
Our overall findings are consistent with prior work demonstrating that there is an intrinsic defect in the proliferation and migration of ECs derived from placentae affected by severe FGR [29]. We further demonstrate that collagens I, III, and IV partially rescue severe FGR EC proliferation. However, no individual substrates appeared to mitigate FGR EC migratory deficiencies that were evident in earlier passage cells. In contrast, our findings of similar migration between control and severe FGR ECs at a later ex vivo passage run counter to prior research. While our laboratory had previously validated other fetoplacental EC properties through the fifth passage, including angiogenic tube formation, this had not previously been completed for wound scratch assays. Other groups have also shown stability of placental and other types of ECs at the cellular, molecular, and transcriptional levels through the fifth passage [36,37,38]. However, we speculate that passaging our cells may specifically alter the dynamics and function of EC surface receptors such as integrins, which bind to ECM proteins and play a critical role in cellular migration. Although not specific to ECs, it has been demonstrated that a higher passage number of various cell types results in differential integrin subcellular localization and rates of trafficking [35,39,40,41].
We did not uncover evidence of differential adhesion among placental ECs, either control or FGR. It is apparent that adhesion and apoptosis of other placental cells plays a critical role in obstetric pathology including FGR [35,42,43,44]. The fact that ECs adhered differently to various ECM substrates points to the critical role of adhesion in angiogenic function and suggests that there might be other ways in which adhesion differs, particularly given the unique ECM patterning in severe FGR. With regard to apoptosis, we did not find any evidence of cleaved caspase-3 in control or FGR ECs regardless of substrate. This suggests that excessive apoptosis is not a primary mechanism underlying impaired angiogenesis in severe FGR. However, it is certainly plausible that the complexities of ECM (that are not recapitulated by individual substrates) may induce either intrinsic or extrinsic apoptotic signaling pathways.
While we were not powered to detect sex-specific differences, we did see evidence of improved EC migration (both control and severe FGR) in cells isolated from placentae of female compared to male fetuses. Interestingly, these sex-specific differences were not evident in adhesion or proliferation. These novel findings suggest that fetal sex may mediate certain angiogenic properties of fetoplacental ECs in severe FGR. Future investigation with sample sizes powered to detect sex-specific differences is warranted.
It is well-established that ECM biochemically and structurally impacts cellular organization and physiological functions. For instance, on an individual protein level, integrin–collagen I interactions in dermal microvascular ECs have been shown to promote cell survival and inhibit apoptosis [45]. Furthermore, ligand binding of collagen I-specific integrins results in down-regulation of signaling pathways, induction of actin polymerization, and formation of prominent stress fibers, which are required for cellular migration [46]. Notably, however, these findings were specific to ECs and were not seen in fibroblasts exposed to collagen I [46]. This suggests that matrix effects are specific to cell type and further support the importance of ECM, in particular, on angiogenesis.
A strength of our research is the use of clinically relevant, primarily isolated human placental cells from well-validated subjects with clear FGR or control phenotypes. However, this study is limited by its focus on the effects of individual exogenous ECM substrates and the use of a single but uniform concentration of each individual ECM protein. Future directions should include evaluation of EC angiogenic properties in the setting of different combinations and patterning of ECM proteins. The healthy placental ECM has been previously characterized through data-mining of a cDNA library, and a more extensive, proteomic cataloging of the ECM composition in uncomplicated and severe FGR placentae may also better guide future investigations into candidate proteins [47]. Additionally, other characteristics of the placental ECM, such as mechanical stiffness, which is increased in severe FGR, should be assessed for their angiogenic consequences [48,49]. As EC–ECM interactions are bi-directional, investigational efforts should also be undertaken to characterize how FGR ECs in turn regulate ECM composition [23]. Finally, angiogenesis is a dynamic process across placental development, and exploration of the effects of the ECM on EC properties at different gestational ages should be undertaken [26].
In summary, we have detected diminished proliferation and migration of fetoplacental ECs in severe FGR. This impaired angiogenic profile is not predicated on a single ECM protein, although collagens I, III, and IV may actually promote severe FGR EC migration. This confirms that the complexities of placental villous stroma, ranging from composition, architecture, stiffness, growth factor sequestration, capacity for remodeling, and sex-specific characteristics, all require further investigation. A detailed comprehension of the impaired angiogenesis characteristic of severe FGR is essential to identifying preventative and treatment strategies of this important obstetric pathology.

Supplementary Materials

The following are available online at https://www.mdpi.com/article/10.3390/cells12192339/s1, Figure S1: No sex-specific differences in control or FGR EC adhesion are detected. OD: optical density; Figure S2: No sex-specific differences in control or FGR EC proliferation are detected; Figure S3: Representative wound scratch images demonstrate significant differences in migratory capacity in the presence of certain ECM substrates. Relative wound density, defined as the proportion of the initial wound scratch occupied by cells, was determined for all images with quantification in Figure 4. This method accounts for changes in background, non-wound, and wound density at each time point, thereby controlling for potential differences in wound scratch size and any variation in confluence at the time the scratch is generated. Yellow scale bar: 400 μm; Figure S4: Both control and severe FGR ECs isolated from placentae of female fetuses display enhanced migratory potential as compared to their male counterparts. Significant differences at specific timepoints based on post hoc comparison are depicted in the graphs; Figure S5: Control and FGR ECs at fifth passage migrate similarly across all ECM proteins, with the exception of collagen I.

Author Contributions

Conceptualization: E.J.S.; methodology: L.S., S.J., D.L.G. and E.J.S.; software: L.S., A.R.F., S.J., D.L.G. and E.J.S.; validation: L.S., A.R.F., S.J., C.R.D., D.L.G. and E.J.S.; formal analysis: L.S. and A.R.F.; investigation: L.S. and A.R.F.; resources: A.R.F., S.J., C.R.D. and D.L.G.; data curation: L.S. and A.R.F.; writing—original draft preparation: L.S.; writing—reviewing and editing: A.R.F., S.J., D.L.G. and E.J.S.; supervision: E.J.S.; project administration: E.J.S.; funding acquisition: L.S. and E.J.S. All authors have read and agreed to the published version of the manuscript.

Funding

National Institutes of Health R01HL119846 (E.J.S, principal investigator), National Institutes of Health T32HD007168 (L.S., appointee; Paul Rozance, principal investigator).

Institutional Review Board Statement

The Colorado Multiple Institutional Review Board approved this research through project numbers 15-0365 (Emily Su, principal investigator, dated 01/31/20) and 14-1073 (Thomas Jansson, principal investigator, dated 07/06/17).

Informed Consent Statement

Informed consent was obtained from all subjects involved in this study.

Data Availability Statement

Data supporting the reported results will be made available upon request to the corresponding author.

Acknowledgments

This manuscript is in memoriam of co-author Carla Rey Diaz, who made significant contributions to this project prior to her passing. The team acknowledges the support of the University of Colorado School of Medicine Cell Technologies Shared Resource in acquisition of live cell microscopy imaging and production of wound scratches and the Perinatal Research Core in identification and recruitment of subjects.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Society for Maternal-Fetal Medicine (SMFM); Martins, J.G.; Biggio, J.R.; Abuhamad, A. Society for Maternal Fetal Medicine. Consult series #52: Diagnosis and management of fetal growth restriction. Am. J. Obstet. Gynecol. 2020, 223, 2–17. [Google Scholar] [CrossRef]
  2. Bernstein, I.M.; Horbar, J.D.; Badger, G.J.; Ohlsson, A.; Golan, A. Morbidity and mortality among very-low-birth-weight neonates with intrauterine growth restriction. Am. J. Obstet. Gynecol. 2000, 182, 198–206. [Google Scholar] [CrossRef] [PubMed]
  3. Frøen, J.F.; Gardosi, J.O.; Thurmann, A.; Francis, A.; Stray-Pedersen, B. Restricted fetal growth in sudden intrauterine unexplained death. Acta. Obstet. Gynecol. Scand. 2004, 83, 801–807. [Google Scholar] [CrossRef] [PubMed]
  4. Chan, P.Y.L.; Morris, J.M.; Leslie, G.I.; Kelly, P.J.; Eileen D., M. Gallery The Long-Term Effects of Prematurity and Intrauterine Growth Restriction on Cardiovascular, Renal, and Metabolic Function. Int. J. Pediatr. 2010, 2010, 1–10. [Google Scholar] [CrossRef] [PubMed]
  5. Gordijn, S.J.; Beune, I.M.; Thilaganathan, B.; Papageorghiou, A.; Baschat, A.A.; Baker, P.N.; Silver, R.M.; Wynia, K.; Ganzevoort, W. Consensus definition of fetal growth restriction: A Delphi procedure. Ultrasound Obstet. Gynecol. 2016, 48, 333–339. [Google Scholar] [CrossRef]
  6. Unterscheider, J.; O’donoghue, K.; Daly, S.; Geary, M.P.; Kennelly, M.M.; McAuliffe, F.M.; Hunter, A.; Morrison, J.J.; Burke, G.; Dicker, P.; et al. Fetal growth restriction and the risk of perinatal mortality–case studies from the multicentre PORTO study. BMC Pregnancy Childbirth 2014, 14, 63. [Google Scholar] [CrossRef]
  7. Dall’Asta, A.; Brunelli, V.; Prefumo, F.; Frusca, T.; Lees, C.C. Early onset fetal growth restriction. Matern. Health Neonatol. Perinatol. 2017, 3, 1–12. [Google Scholar] [CrossRef]
  8. Lingam, I.; Okell, J.; Maksym, K.; Spencer, R.; Peebles, D.; Buquis, G.; Ambler, G.; Morsing, E.; Ley, D.; Singer, D.; et al. Neonatal outcomes following early fetal growth restriction: A subgroup analysis of the EVERREST study. Arch. Dis. Child. Fetal Neonatal Ed. 2023. [Google Scholar] [CrossRef]
  9. Caradeux, J.; Martinez-Portilla, R.; Basuki, T.; Kiserud, T.; Figueras, F. Risk of fetal death in growth-restricted fetuses with umbilical and/or ductus venosus absent or reversed end-diastolic velocities before 34 weeks of gestation: A systematic review and meta-analysis. Am. J. Obstet. Gynecol. 2018, 218, S774–S782.e21. [Google Scholar] [CrossRef]
  10. Bligard, K.H.; Xu, X.; Raghuraman, N.; Dicke, J.M.; Odibo, A.O.; Frolova, A.I. Clinical significance of umbilical artery intermittent vs persistent absent end-diastolic velocity in growth-restricted fetuses. Am. J. Obstet. Gynecol. 2022, 227, 519.e1–519.e9. [Google Scholar] [CrossRef]
  11. Jang, D.G.; Jo, Y.S.; Lee, S.J.; Kim, N.; Lee, G.S.R. Perinatal outcomes and maternal clinical characteristics in IUGR with absent or reversed end-diastolic flow velocity in the umbilical artery. Arch. Gynecol. Obstet. 2010, 284, 73–78. [Google Scholar] [CrossRef] [PubMed]
  12. Sacchi, C.; Marino, C.; Nosarti, C.; Vieno, A.; Visentin, S.; Simonelli, A. Association of intrauterine growth restriction and small for gestational age status with childhood cognitive outcomes: A systematic review and meta-analysis. JAMA Pediatr. 2020, 174, 772–781. [Google Scholar] [CrossRef] [PubMed]
  13. Sehgal, A.; Skilton, M.R.; Crispi, F. Human fetal growth restriction: A cardiovascular journey through to adolescence. J. Dev. Orig. Heal. Dis. 2016, 7, 626–635. [Google Scholar] [CrossRef] [PubMed]
  14. Burton, G.; Jauniaux, E. Pathophysiology of placental-derived fetal growth restriction. Am. J. Obstet. Gynecol. 2018, 218, S745–S761. [Google Scholar] [CrossRef]
  15. Kingdom, J.C.P.; Burrell, S.J.; Kaufmann, P. Pathology and clinical implications of abnormal umbilical artery Doppler waveforms. Ultrasound Obstet. Gynecol. 1997, 9, 271–286. [Google Scholar] [CrossRef]
  16. Krebs, C.; Macara, L.M.; Leiser, R.; Bowman, A.W.; Greer, I.A.; Kingdom, J.C. Intrauterine growth restriction with absent end-diastolic flow velocity in the umbilical artery is associated with maldevelopment of the placental terminal villous tree. Am. J. Obstet. Gynecol. 1996, 175, 1534–1542. [Google Scholar] [CrossRef]
  17. Mayhew, T.M.; Charnock-Jones, D.S.; Kaufmann, P. Aspects of human fetoplacental vasculogenesis and angiogenesis. Iii. Changes in complicated pregnancies. Placenta 2004, 25, 127–139. [Google Scholar] [CrossRef]
  18. Mayhew, T.; Ohadike, C.; Baker, P.; Crocker, I.; Mitchell, C.; Ong, S. Stereological Investigation of Placental Morphology in Pregnancies Complicated by Pre-eclampsia with and without Intrauterine Growth Restriction. Placenta 2003, 24, 219–226. [Google Scholar] [CrossRef]
  19. Todros, T.; Sciarrone, A.; Piccoli, E.; Guiot, C.; Kaufmann, P.; Kingdom, J. Umbilical doppler waveforms and placental villous angiogenesis in pregnancies complicated by fetal growth restriction. Obstet. Gynecol. 1999, 93, 499–503. [Google Scholar] [CrossRef]
  20. Baergen, R.N.; Burton, G.J.; Kaplan, C.G. Benirschke’s Pathology of the Human Placenta, 7th ed.; Springer: Berlin, Germany, 2022. [Google Scholar]
  21. Li, Y.; A Lorca, R.; Su, E.J. Molecular and cellular underpinnings of normal and abnormal human placental blood flows. J. Mol. Endocrinol. 2018, 60, R9–R22. [Google Scholar] [CrossRef]
  22. Maulik, D.; Evans, J.F.; Ragolia, L. Fetal Growth Restriction: Pathogenic Mechanisms. Clin. Obstet. Gynecol. 2006, 49, 219–227. [Google Scholar] [CrossRef]
  23. Davis, G.E.; Senger, D.R. Endothelial extracellular matrix: Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization. Circ. Res. 2005, 97, 1093–1107. [Google Scholar] [CrossRef] [PubMed]
  24. Belotti, D.; Foglieni, C.; Resovi, A.; Giavazzi, R.; Taraboletti, G. Targeting angiogenesis with compounds from the extracellular matrix. Int. J. Biochem. Cell Biol. 2011, 43, 1674–1685. [Google Scholar] [CrossRef] [PubMed]
  25. Dye, J.F.; Lawrence, L.; Linge, C.; Leach, L.; Firth, J.A.; Clark, P. Distinct Patterns of Microvascular Endothelial Cell Morphology Are Determined by Extracellular Matrix Composition. J. Endothel. Cell Res. 2004, 11, 151–167. [Google Scholar] [CrossRef]
  26. Burton, G.J.; Charnock-Jones, D.S.; Jauniaux, E. Regulation of vascular growth and function in the human placenta. Reproduction 2009, 138, 895–902. [Google Scholar] [CrossRef]
  27. Torry, D.S.; Hinrichs, M.; Torry, R.J. Determinants of Placental Vascularity. Am. J. Reprod. Immunol. 2004, 51, 257–268. [Google Scholar] [CrossRef] [PubMed]
  28. Rajashekhar, G.; Loganath, A.; Roy, A.; Chong, S.; Wong, Y. Extracellular matrix-dependent regulation of angiogenin expression in human placenta. J. Cell. Biochem. 2005, 96, 36–46. [Google Scholar] [CrossRef]
  29. Ji, S.; Gumina, D.; McPeak, K.; Moldovan, R.; Post, M.D.; Su, E.J. Human placental villous stromal extracellular matrix regulates fetoplacental angiogenesis in severe fetal growth restriction. Clin. Sci. 2021, 135, 1127–1143. [Google Scholar] [CrossRef]
  30. Su, E.J.; Xin, H.; Yin, P.; Dyson, M.; Coon, J.; Farrow, K.N.; Mestan, K.K.; Ernst, L.M. Impaired fetoplacental angiogenesis in growth-restricted fetuses with abnormal umbilical artery doppler velocimetry is mediated by aryl hydrocarbon receptor nuclear translocator (ARNT). J. Clin. Endocrinol. Metab. 2015, 100, E30–E40. [Google Scholar] [CrossRef]
  31. Amenta, P.S.; Gay, S.; Vaheri, A.; Martinez-Hernandez, A. The Extracellular Matrix is an Integrated Unit: Ultrastructural Localization of Collagen Types I, III, IV, V, VI, Fibronectin, and Laminin in Human Term Placenta. Collagen Relat. Res. 1986, 6, 125–152. [Google Scholar] [CrossRef]
  32. Lala, P.K.; Nandi, P. Mechanisms of trophoblast migration, endometrial angiogenesis in preeclampsia: The role of decorin. Cell Adhes. Migr. 2016, 10, 111–125. [Google Scholar] [CrossRef] [PubMed]
  33. Ponder, K.G.; Boise, L.H. The prodomain of caspase-3 regulates its own removal and caspase activation. Cell Death Discov. 2019, 5, 1–10. [Google Scholar] [CrossRef] [PubMed]
  34. Huang, Z.; Huang, S.; Song, T.; Yin, Y.; Tan, C. Placental Angiogenesis in Mammals: A Review of the Regulatory Effects of Signaling Pathways and Functional Nutrients. Adv. Nutr. Int. Rev. J. 2021, 12, 2415–2434. [Google Scholar] [CrossRef]
  35. Gumina, D.L.; Ji, S.; Flockton, A.; McPeak, K.; Stich, D.; Moldovan, R.; Su, E.J. Dysregulation of integrin alpha-v-beta-3 and alpha-5-beta-1 impedes migration of placental endothelial cells in fetal growth restriction. Development 2022, 149, dev200717. [Google Scholar] [CrossRef]
  36. Marcu, R.; Choi, Y.J.; Xue, J.; Fortin, C.L.; Wang, Y.; Nagao, R.J.; Xu, J.; MacDonald, J.W.; Bammler, T.K.; Murry, C.E.; et al. Human Organ-Specific Endothelial Cell Heterogeneity. iScience 2018, 4, 20–35. [Google Scholar] [CrossRef]
  37. Lang, I.; Pabst, M.A.; Hiden, U.; Blaschitz, A.; Dohr, G.; Hahn, T.; Desoye, G. Heterogeneity of microvascular endothelial cells isolated from human term placenta and macrovascular umbilical vein endothelial cells. Eur. J. Cell Biol. 2003, 82, 163–173. [Google Scholar] [CrossRef] [PubMed]
  38. Liao, H.; He, H.; Chen, Y.; Zeng, F.; Huang, J.; Wu, L.; Chen, Y. Effects of long-term serial cell passaging on cell spreading, migration, and cell-surface ultrastructures of cultured vascular endothelial cells. Cytotechnology 2013, 66, 229–238. [Google Scholar] [CrossRef]
  39. De Luca, M.; Pellegrini, G.; Bondanza, S.; Cremona, O.; Savoia, P.; Cancedda, R.; Marchisio, P.C. The control of polarized integrin topography and the organization of adhesion-related cytoskeleton in normal human keratinocytes depend upon number of passages in culture and ionic environment. Exp. Cell Res. 1992, 202, 142–150. [Google Scholar] [CrossRef]
  40. Lee, W.; McCulloch, C. Deregulation of Collagen Phagocytosis in Aging Human Fibroblasts: Effects of Integrin Expression and Cell Cycle. Exp. Cell Res. 1997, 237, 383–393. [Google Scholar] [CrossRef]
  41. Meng, Y.; Eshghi, S.; Li, Y.J.; Schmidt, R.; Schaffer, D.V.; Healy, K.E. Characterization of integrin engagement during defined human embryonic stem cell culture. FASEB J. 2009, 24, 1056–1065. [Google Scholar] [CrossRef]
  42. Sharp, A.N.; Heazell, A.E.; Crocker, I.P.; Mor, G. Placental Apoptosis in Health and Disease. Am. J. Reprod. Immunol. 2010, 64, 159–169. [Google Scholar] [CrossRef]
  43. Whitley, G.S.J.; Cartwright, J.E. Trophoblast-mediated spiral artery remodelling: A role for apoptosis. J. Anat. 2009, 215, 21–26. [Google Scholar] [CrossRef]
  44. Lylla, F.; Hayman, R.G.; Ashworth, J.R.; Duffie, E.; Baker, P.N. Relationship of Cell Adhesion Molecule Expression to Endothelium-Dependent Relaxation in Normal Pregnancy and Pregnancies Complicated With Preeclampsia or Fetal Growth Restriction. J. Soc. Gynecol. Investig. 1999, 6, 196–201. [Google Scholar] [CrossRef]
  45. Perruzzi, C.A.; Whelan, M.C.; Senger, D.R.; de Fougerolles, A.R.; Koteliansky, V.E.; Westlin, W.F. Functional overlap and cooperativity among alpha-v and beta-1 integrin subfamilies during skin angiogenesis. J. Invest. Dermatol. 2003, 120, 1100–1109. [Google Scholar] [CrossRef] [PubMed]
  46. Whelan, M.C.; Senger, D.R. Collagen I Initiates Endothelial Cell Morphogenesis by Inducing Actin Polymerization through Suppression of Cyclic AMP and Protein Kinase A. J. Biol. Chem. 2003, 278, 327–334. [Google Scholar] [CrossRef] [PubMed]
  47. Chen, C.; Aplin, J. Placental Extracellular Matrix: Gene Expression, Deposition by Placental Fibroblasts and the Effect of Oxygen. Placenta 2003, 24, 316–325. [Google Scholar] [CrossRef] [PubMed]
  48. Saw, S.N.; Low, J.Y.R.; Ong, M.H.H.; Poh, Y.W.; Mattar, C.N.Z.; Biswas, A.; Yap, C.H. Hyperelastic Mechanical Properties of Ex Vivo Normal and Intrauterine Growth Restricted Placenta. Ann. Biomed. Eng. 2018, 46, 1066–1077. [Google Scholar] [CrossRef]
  49. Eroğlu, H.; Tolunay, H.E.; Tonyalı, N.V.; Orgul, G.; Şahin, D.; Yücel, A. Comparison of placental elasticity in normal and intrauterine growth retardation pregnancies by ex vivo strain elastography. Arch. Gynecol. Obstet. 2020, 302, 109–115. [Google Scholar] [CrossRef]
Cells 12 02339 g001
Figure 1. Experimental design. All experiments were performed with a minimum of technical triplicates. There were 8 subjects in each group unless otherwise indicated.
Figure 1. Experimental design. All experiments were performed with a minimum of technical triplicates. There were 8 subjects in each group unless otherwise indicated.
Cells 12 02339 g001
Cells 12 02339 g002
Figure 2. EC adhesion to ECM substrates is not different between control and severe FGR phenotypes. Graphical representation of EC adhesive properties to ECM substrates shows that adhesion to any substrate is not significantly different between control (n = 8) and severe FGR (n = 8) ECs. Statistical differences detected between substrates are indicated (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). OD: optical density.
Figure 2. EC adhesion to ECM substrates is not different between control and severe FGR phenotypes. Graphical representation of EC adhesive properties to ECM substrates shows that adhesion to any substrate is not significantly different between control (n = 8) and severe FGR (n = 8) ECs. Statistical differences detected between substrates are indicated (* p < 0.05, ** p < 0.01, *** p < 0.001, **** p < 0.0001). OD: optical density.
Cells 12 02339 g002
Cells 12 02339 g003
Figure 3. Control ECs proliferate more robustly than their growth-restricted counterparts, although collagens I, III, and IV appear to partially mitigate severe FGR EC proliferation. (A) Overall, control ECs (n = 7) demonstrate increased proliferation over five days relative to severe FGR cells (n = 7), with statistical differences at days 3, 4, and 5 on post hoc comparison (* p < 0.05, ** p < 0.01, *** p < 0.001). (B) This difference in proliferation was statistically negated once stratified by individual substrate. (C) Comparison of individual substrates to uncoated conditions in both control and severe FGR ECs show that only collagens I, III, and IV partially mitigate FGR EC proliferative impairment (C: p values comparing each individual ECM substrate to lack of substrate for control ECs; F: p values comparing each individual ECM substrate to lack of ECM protein for severe FGR ECs). Statistically significant findings are bolded. Data represent four technical replicates per each of the 14 subjects.
Figure 3. Control ECs proliferate more robustly than their growth-restricted counterparts, although collagens I, III, and IV appear to partially mitigate severe FGR EC proliferation. (A) Overall, control ECs (n = 7) demonstrate increased proliferation over five days relative to severe FGR cells (n = 7), with statistical differences at days 3, 4, and 5 on post hoc comparison (* p < 0.05, ** p < 0.01, *** p < 0.001). (B) This difference in proliferation was statistically negated once stratified by individual substrate. (C) Comparison of individual substrates to uncoated conditions in both control and severe FGR ECs show that only collagens I, III, and IV partially mitigate FGR EC proliferative impairment (C: p values comparing each individual ECM substrate to lack of substrate for control ECs; F: p values comparing each individual ECM substrate to lack of ECM protein for severe FGR ECs). Statistically significant findings are bolded. Data represent four technical replicates per each of the 14 subjects.
Cells 12 02339 g003
Cells 12 02339 g004
Figure 4. Growth-restricted ECs migrate more slowly than control ECs, and this effect is not rescued by any individual ECM substrate. (A) Control ECs (n = 8) at passages 3–4 exhibit improved migratory potential relative to severe FGR cells (n = 8), with post hoc statistical differences at all time points except for 0 and 24 h (* p < 0.05, *** p < 0.001). (B) This impairment in FGR EC migration is persistent in the setting of no ECM protein, fibronectin, collagen I, and laminin. (C) Migration of control or severe FGR EC in the setting of individual ECM substrates was compared to migration in the absence of substrate. Fibronectin, collagen I, and laminin do not enhance FGR EC migration. Neither control nor FGR EC migration was significantly altered in the presence of any individual ECM substrate. (C: p values comparing each individual ECM substrate to lack of ECM protein for control ECs; F: p values comparing each individual ECM substrate to lack of ECM protein for severe FGR ECs). Statistically significant findings are bolded. Data represent four technical replicates per each of the 16 subjects.
Figure 4. Growth-restricted ECs migrate more slowly than control ECs, and this effect is not rescued by any individual ECM substrate. (A) Control ECs (n = 8) at passages 3–4 exhibit improved migratory potential relative to severe FGR cells (n = 8), with post hoc statistical differences at all time points except for 0 and 24 h (* p < 0.05, *** p < 0.001). (B) This impairment in FGR EC migration is persistent in the setting of no ECM protein, fibronectin, collagen I, and laminin. (C) Migration of control or severe FGR EC in the setting of individual ECM substrates was compared to migration in the absence of substrate. Fibronectin, collagen I, and laminin do not enhance FGR EC migration. Neither control nor FGR EC migration was significantly altered in the presence of any individual ECM substrate. (C: p values comparing each individual ECM substrate to lack of ECM protein for control ECs; F: p values comparing each individual ECM substrate to lack of ECM protein for severe FGR ECs). Statistically significant findings are bolded. Data represent four technical replicates per each of the 16 subjects.
Cells 12 02339 g004
Cells 12 02339 g005
Figure 5. There is no evidence of apoptosis for control or severe FGR ECs cultured in the presence or absence of any individual ECM substrate. (A) Capillary immunoblot demonstrates that total caspase-3, represented by the 36 kDa marker, is expressed in all ECs (n = 8 for control and n = 8 for severe FGR) regardless of the presence or absence of individual ECM substrates. (B) Cleaved caspase-3, a marker of apoptosis and detected at 17 and 19 kDa as denoted by the positive control, was not detected among all ECs and all substrates. Total protein normalization within the capillary immunoblots is shown in blue. All immunoblots for each of the 16 subjects produced identical results with presence of total caspase-3 and absence of cleaved caspase-3, with the exception of the positive control for apoptosis.
Figure 5. There is no evidence of apoptosis for control or severe FGR ECs cultured in the presence or absence of any individual ECM substrate. (A) Capillary immunoblot demonstrates that total caspase-3, represented by the 36 kDa marker, is expressed in all ECs (n = 8 for control and n = 8 for severe FGR) regardless of the presence or absence of individual ECM substrates. (B) Cleaved caspase-3, a marker of apoptosis and detected at 17 and 19 kDa as denoted by the positive control, was not detected among all ECs and all substrates. Total protein normalization within the capillary immunoblots is shown in blue. All immunoblots for each of the 16 subjects produced identical results with presence of total caspase-3 and absence of cleaved caspase-3, with the exception of the positive control for apoptosis.
Cells 12 02339 g005
Table 1. Demographic and clinical characteristics.
Table 1. Demographic and clinical characteristics.
Control (n = 8)Severe Fetal Growth Restriction (n = 8)Difference
(p Value)
Maternal age (years)34 (26–39)32 (23–38)0.34
Nulliparity0 (0%)3 (38%)0.03
Gestational age at delivery (weeksdays)391 (390–393)283 (243–341)<0.0001
Neonatal sex (female)4 (50%)3 (38%)0.85
Birth weight (grams)3220 (2898-3840)647 (370–1425)<0.0001
Fenton percentile43 (14–85)3 (1–7)<0.01
Presented as mean (range) or n (%). Statistically significant differences indicated with bold font.
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Sayres, L.; Flockton, A.R.; Ji, S.; Rey Diaz, C.; Gumina, D.L.; Su, E.J. Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins. Cells 2023, 12, 2339. https://doi.org/10.3390/cells12192339

AMA Style

Sayres L, Flockton AR, Ji S, Rey Diaz C, Gumina DL, Su EJ. Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins. Cells. 2023; 12(19):2339. https://doi.org/10.3390/cells12192339

Chicago/Turabian Style

Sayres, Lauren, Amanda R. Flockton, Shuhan Ji, Carla Rey Diaz, Diane L. Gumina, and Emily J. Su. 2023. "Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins" Cells 12, no. 19: 2339. https://doi.org/10.3390/cells12192339

APA Style

Sayres, L., Flockton, A. R., Ji, S., Rey Diaz, C., Gumina, D. L., & Su, E. J. (2023). Angiogenic Function of Human Placental Endothelial Cells in Severe Fetal Growth Restriction Is Not Rescued by Individual Extracellular Matrix Proteins. Cells, 12(19), 2339. https://doi.org/10.3390/cells12192339

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop